KMTS

Hot Air

Kestra Medical Technologies, Ltd. · Healthcare · United States · $1.7B cap · $13.9M/day traded

$29.55 -1.9% · close 10 Nov · scored 11 Nov

Hot Air: Strong momentum and nothing else: weak business, rich price.

29
Score
Get score and insider alerts
Quality
28
Value
22
Momentum
67

As of 11 Nov 2026, the MoatMap Score for Kestra Medical Technologies, Ltd. (KMTS) is 29/100, ranked against 25,000+ stocks in 38 markets (Quality 28, Value 22, Momentum 67, each scored against its sector).

Does the score work? Each tenth of the ranking, tracked monthly. See the record →

P/E (TTM)
—
peers 25.9x
ROE
-73.7%
peers -30.0%
D/E
0.3x
peers 0.2x
Dividend %
—
trailing yield

ABOUT KESTRA MEDICAL TECHNOLOGIES, LTD.

Read

Kestra Medical Technologies specializes in the development and commercialization of wearable medical devices, primarily focusing on cardiac care and remote patient monitoring. The company aims to improve patient outcomes and comfort through its innovative, discreet, and easy-to-use technology. Kestra targets a niche in personalized, preventative, and responsive cardiac management solutions.

FINANCIAL SUMMARY (USD)

Year2021202320242025CAGRTTM2027E2028EFwd CAGR
Revenue07.6M27.8M59.8M180.0%106.7M88.6M123.2M27.2%
EPS-1.71-4.36-5.07-5.13—-2.67-2.45-2.06—
Shares49.5M49.5M49.5M51.3M+3.7%59.6M———
Debt22.8M39.1M45.2M44.3M18.0%76.4M———
Equity1.8M-117.6M-209.4M205.4M228.4%————
Op CF-29.9M-69.6M-72.2M-77.6M—-87.7M———
Inv CF-0.3M-15.5M-12.2M-23.3M—————
Fin CF48.8M96.1M77.7M330.3M—————
PRICE (1Y) · USD+4.5%
25.526.828.029.330.630 Sep21 Oct10 Nov
SMA 50SMA 200

Price checkIn an uptrendExperimental

Above its 200-day average and 7% below its 52-week high.

SwingsVery bumpy

Swung more than 78% of stocks we rank over the past year (volatility 64% a year).

How this is worked out

The MoatMap Score weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.

The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.

In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.

What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.

What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.

Calm is not safe: a calm stock can still slide steadily.

Rules fixed before any data was fetched. Describes the chart, not a recommendation.

Close
$29.55
RSI (14)
60.2
52-Week Range-7.4% from high
Low $17.34High $31.91

SCORE BREAKDOWN

Quality
28
ROIC
-46.1%17.3
ROE
-73.7%12.7
GP/Assets
16.0%36.9
Op. Margin
-121.6%15.5
FCF/Assets
-34.4%12.9
Piotroski
549.5
Int. Cover
-18.8x17.9
D/E Ratio
0.34x37.8
Current Ratio
4.69x70.8
Value
22
P/E (TTM)
—N/A
EV/EBITDA
-11.9x25.0
P/FCF
—N/A
P/B
7.7x13.5
P/S
16.1x16.4
Div Yield
—N/A
Momentum
67
52W High %
93%87.6
RS 6M
35%86.1
SMA 50/200
1.13x83.5
EPS Rev 4W
0.0%51.2
EPS Rev 12W
+0.9%64.9
EPS Improve
+23%38.2
Q Growth
—N/A

FUNDAMENTALS

Market Cap
$1.7B
P/E (Forward)
-14.0x
Gross Margin
53.9%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of KMTS are excluded.

TickerCompanyMkt CapScore
KMTSKestra Medical Technologies, Ltd.(you)$1.7B29
STAASTAAR Surgical Company$1.1B31
PLSEPulse Biosciences, Inc.$3.8B28
AZTAAzenta, Inc.$1.6B45
LMATLeMaitre Vascular, Inc.$1.9B50
XRAYDENTSPLY SIRONA Inc.$1.9B51
ANGOAngioDynamics, Inc.$520M34
WRBYWarby Parker Inc.$3.2B54
ATRCAtriCure, Inc.$3.0B61
OSUROraSure Technologies, Inc.$285M40

Peer medians: ROE -30.0% · P/E 25.9x · Gross margin 63.3%

Company Deep Dive

A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.

Request Deep Dive(50 Feathers)

Kestra Medical Technologies, Ltd. (KMTS): Stock Score Summary

Kestra Medical Technologies, Ltd. (KMTS) has a MoatMap Score of 29/100 based on Quality (28/100), Value (22/100), and Momentum (67/100) factor scores.

Kestra Medical Technologies specializes in the development and commercialization of wearable medical devices, primarily focusing on cardiac care and remote patient monitoring. The company aims to improve patient outcomes and comfort through its innovative, discreet, and easy-to-use technology. Kestra targets a niche in personalized, preventative, and responsive cardiac management solutions.

Director dealings

From 2 Jan 2026 to 11 Nov 2026, MoatMap's records hold 41 sales and 1 purchase of Kestra Medical Technologies, Ltd. (KMTS) shares by its directors. The largest: Umberger Traci S sold 100,000 shares at $27.18 on 21 Oct 2026 (about $2.7M).

  • 3 Nov 2026: Moran Timothy P. sold 3,192 shares at $29.56 (about $94K)
  • 29 Oct 2026: Mahboob Vaseem sold 4,788 shares at $30.60 (about $147K)
  • 28 Oct 2026: Mahboob Vaseem sold 39,903 shares at $30.48 (about $1.2M)
  • 27 Oct 2026: Mahboob Vaseem sold 34,809 shares at $30.04 (about $1.0M)
  • 27 Oct 2026: Umberger Traci S sold 30,000 shares at $30.03 (about $901K)
KMTS insider filings, last 180 days

Key Financial Metrics

Price$29.55
Market Cap$1.7B
P/E (Forward)-14.01
Price/Book7.68
Return on Equity-73.7%
Return on Invested Capital-46.1%
Debt/Equity0.34x
Gross Margin53.9%
Operating Margin-121.6%
Revenue Growth59.9%
Free Cash Flow$-123M

Kestra Medical Technologies, Ltd. operates in the Medical Instruments & Supplies industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Kestra Medical Technologies, Ltd.’s (KMTS) MoatMap Score?
The MoatMap Score for Kestra Medical Technologies, Ltd. (KMTS) is 29/100. It is a composite of Quality (28), Value (22), and Momentum (67), each scored against its sector. The composite is then ranked across MoatMap’s universe of 25,000+ stocks.
Does Kestra Medical Technologies, Ltd. have an economic moat?
Kestra Medical Technologies, Ltd. (KMTS) has a Quality factor score of 28/100. Quality blends several measures of profitability and financial strength, led by gross profit to assets, return on invested capital and free cash flow to assets. A high score describes the financial record a durable advantage tends to leave; it does not prove a moat.
What sector is Kestra Medical Technologies, Ltd. in?
Kestra Medical Technologies, Ltd. (KMTS) operates in the Healthcare sector, specifically the Medical Instruments & Supplies industry (United States).